BOCAPS has upgraded Aurobindo Pharma’s rating to ‘Buy’, raising the target price from ₹1,200 to ₹1,728 per share. The company is undergoing a transformation, shifting its focus from APIs to biologics and biosimilars.
Eugia’s sales target of approximately US$ 700 million by FY26E is seen as achievable. Moreover, the EBITDA margin is expected to grow from 20% in FY24 to 24% by FY27E.
Aurobindo Pharma is also the only player to commercialize Pen-G in India, with strong demand for the product across the country.
Disclaimer: This information is based on brokerage reports and is not a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
